# MethylphenIdate for Fatigue in Haematological Cancer

> **NCT03218254** · PHASE3 · UNKNOWN · sponsor: **Henrik Frederiksen** · enrollment: 150 (estimated)

## Conditions studied

- Hematological Cancer

## Interventions

- **DRUG:** Methylphenidate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03218254
- **Lead sponsor:** Henrik Frederiksen
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-06-08
- **Primary completion:** 2021-10-01
- **Final completion:** 2021-10-01
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2018-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03218254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03218254, "MethylphenIdate for Fatigue in Haematological Cancer". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03218254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*